Eli Lilly falls after report of delay in FDA decision on weight-loss pill

Disc Medicine

15/01/2026 11:44

** Eli Lilly LLY.N shares fall 1% to $1,062 premarket after Reuters reports U.S. FDA has delayed decision on company's weight-loss pill to April 10

** The decision was previously expected by late-March

** The drug was tapped for the administration's fast-track review program, which promised decisions in one or two months for a limited number of drugs deemed critical to public health or national security

** FDA also pushed reviews of Disc Medicine's IRON.O rare blood disorder drug and Sanofi's SASY.PA Tzield for type 1 diabetes after agency scientists flagged safety and efficacy concerns, report says

** LLY up 44% over the past year

(Reporting by Tharuniyaa Lakshmi in Bengaluru)

((tharuniyaa@thomsonreuters.com))